vs
百通（BDC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是百通的1.1倍（$772.1M vs $720.1M），Revvity净利率更高（12.7% vs 9.4%，领先3.3%），百通同比增速更快（8.1% vs 5.9%），Revvity自由现金流更多（$161.8M vs $121.3M），过去两年百通的营收复合增速更高（9.2% vs 9.0%）
百通公司是美国上市跨国企业，专注于端到端网络、安全及连接产品的设计、生产与销售，业务覆盖工业自动化解决方案、智能建筑、宽带及5G三大核心领域，为各行业客户提供可靠的通信连接相关产品与服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BDC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$720.1M
营收增速更快
BDC
高出2.3%
5.9%
净利率更高
RVTY
高出3.3%
9.4%
自由现金流更多
RVTY
多$40.5M
$121.3M
两年增速更快
BDC
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $720.1M | $772.1M |
| 净利润 | $67.9M | $98.4M |
| 毛利率 | 36.6% | — |
| 营业利润率 | 12.2% | 14.5% |
| 净利率 | 9.4% | 12.7% |
| 营收同比 | 8.1% | 5.9% |
| 净利润同比 | 16.3% | 3.9% |
| 每股收益（稀释后） | $1.70 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDCRVTY
| Q1 26 | $720.1M | — | ||
| Q4 25 | $720.1M | $772.1M | ||
| Q3 25 | $698.2M | $698.9M | ||
| Q2 25 | $672.0M | $720.3M | ||
| Q1 25 | $624.9M | $664.8M | ||
| Q4 24 | $666.0M | $729.4M | ||
| Q3 24 | $654.9M | $684.0M | ||
| Q2 24 | $604.3M | $691.7M |
净利润BDCRVTY
| Q1 26 | $67.9M | — | ||
| Q4 25 | $67.9M | $98.4M | ||
| Q3 25 | $56.7M | $46.7M | ||
| Q2 25 | $61.0M | $53.9M | ||
| Q1 25 | $51.9M | $42.2M | ||
| Q4 24 | $58.4M | $94.6M | ||
| Q3 24 | $53.7M | $94.4M | ||
| Q2 24 | $49.0M | $55.4M |
毛利率BDCRVTY
| Q1 26 | 36.6% | — | ||
| Q4 25 | 36.6% | — | ||
| Q3 25 | 37.7% | 53.6% | ||
| Q2 25 | 38.5% | 54.5% | ||
| Q1 25 | 39.3% | 56.5% | ||
| Q4 24 | 37.5% | — | ||
| Q3 24 | 37.3% | 56.3% | ||
| Q2 24 | 37.5% | 55.7% |
营业利润率BDCRVTY
| Q1 26 | 12.2% | — | ||
| Q4 25 | 12.2% | 14.5% | ||
| Q3 25 | 10.9% | 11.7% | ||
| Q2 25 | 11.8% | 12.6% | ||
| Q1 25 | 11.6% | 10.9% | ||
| Q4 24 | 10.4% | 16.3% | ||
| Q3 24 | 11.5% | 14.3% | ||
| Q2 24 | 11.4% | 12.4% |
净利率BDCRVTY
| Q1 26 | 9.4% | — | ||
| Q4 25 | 9.4% | 12.7% | ||
| Q3 25 | 8.1% | 6.7% | ||
| Q2 25 | 9.1% | 7.5% | ||
| Q1 25 | 8.3% | 6.4% | ||
| Q4 24 | 8.8% | 13.0% | ||
| Q3 24 | 8.2% | 13.8% | ||
| Q2 24 | 8.1% | 8.0% |
每股收益（稀释后）BDCRVTY
| Q1 26 | $1.70 | — | ||
| Q4 25 | $1.70 | $0.86 | ||
| Q3 25 | $1.41 | $0.40 | ||
| Q2 25 | $1.53 | $0.46 | ||
| Q1 25 | $1.27 | $0.35 | ||
| Q4 24 | $1.41 | $0.77 | ||
| Q3 24 | $1.30 | $0.77 | ||
| Q2 24 | $1.19 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $389.9M | $919.9M |
| 总债务越低越好 | $1.3B | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | — | $12.2B |
| 负债/权益比越低杠杆越低 | 1.02× | — |
8季度趋势，按日历期对齐
现金及短期投资BDCRVTY
| Q1 26 | $389.9M | — | ||
| Q4 25 | $389.9M | $919.9M | ||
| Q3 25 | $314.3M | $931.4M | ||
| Q2 25 | $301.5M | $991.8M | ||
| Q1 25 | $259.0M | $1.1B | ||
| Q4 24 | $370.3M | $1.2B | ||
| Q3 24 | $323.0M | $1.2B | ||
| Q2 24 | $564.8M | $2.0B |
总债务BDCRVTY
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BDCRVTY
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.3B | $7.7B | ||
| Q3 24 | $1.2B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B |
总资产BDCRVTY
| Q1 26 | — | — | ||
| Q4 25 | $3.5B | $12.2B | ||
| Q3 25 | $3.4B | $12.1B | ||
| Q2 25 | $3.4B | $12.4B | ||
| Q1 25 | $3.3B | $12.4B | ||
| Q4 24 | $3.3B | $12.4B | ||
| Q3 24 | $3.3B | $12.8B | ||
| Q2 24 | $3.5B | $13.4B |
负债/权益比BDCRVTY
| Q1 26 | 1.02× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $354.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $121.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 16.8% | 21.0% |
| 资本支出强度资本支出/营收 | 18.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 5.23× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $364.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BDCRVTY
| Q1 26 | $354.9M | — | ||
| Q4 25 | $160.4M | $182.0M | ||
| Q3 25 | $105.0M | $138.5M | ||
| Q2 25 | $82.0M | $134.3M | ||
| Q1 25 | $7.4M | $128.2M | ||
| Q4 24 | $174.7M | $174.2M | ||
| Q3 24 | $91.7M | $147.9M | ||
| Q2 24 | $83.0M | $158.6M |
自由现金流BDCRVTY
| Q1 26 | $121.3M | — | ||
| Q4 25 | $121.3M | $161.8M | ||
| Q3 25 | $65.3M | $120.0M | ||
| Q2 25 | $56.9M | $115.5M | ||
| Q1 25 | $-24.8M | $112.2M | ||
| Q4 24 | $116.4M | $149.8M | ||
| Q3 24 | $67.2M | $125.6M | ||
| Q2 24 | $61.0M | $136.6M |
自由现金流率BDCRVTY
| Q1 26 | 16.8% | — | ||
| Q4 25 | 16.8% | 21.0% | ||
| Q3 25 | 9.4% | 17.2% | ||
| Q2 25 | 8.5% | 16.0% | ||
| Q1 25 | -4.0% | 16.9% | ||
| Q4 24 | 17.5% | 20.5% | ||
| Q3 24 | 10.3% | 18.4% | ||
| Q2 24 | 10.1% | 19.7% |
资本支出强度BDCRVTY
| Q1 26 | 18.9% | — | ||
| Q4 25 | 5.4% | 2.6% | ||
| Q3 25 | 5.7% | 2.6% | ||
| Q2 25 | 3.7% | 2.6% | ||
| Q1 25 | 5.2% | 2.4% | ||
| Q4 24 | 8.8% | 3.4% | ||
| Q3 24 | 3.7% | 3.3% | ||
| Q2 24 | 3.6% | 3.2% |
现金转化率BDCRVTY
| Q1 26 | 5.23× | — | ||
| Q4 25 | 2.36× | 1.85× | ||
| Q3 25 | 1.85× | 2.97× | ||
| Q2 25 | 1.34× | 2.49× | ||
| Q1 25 | 0.14× | 3.03× | ||
| Q4 24 | 2.99× | 1.84× | ||
| Q3 24 | 1.71× | 1.57× | ||
| Q2 24 | 1.69× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDC
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
